Endometrial Priming for Embryo Transfer

Phase 4

Completed

• Conditions: Sterility
• Interventions: Drug: Oral strogen; Drug: Transdermal strogen

• Registration Number: NCT01430650
• Lead Sponsor: Parc de Salut Mar

Brief Summary

The aim of this trial is compare two different endometrial priming protocols

* women that receive oral estrogens

* women that receive transdermal estrogens

Detailed Description

Not available

Study Timeline

• Study Start: 2010-07
• Study First Submitted: 2011-06-20
• Study First Submitted QC: 2011-09-07
• Study First Posted: 2011-09-08
• Primary Completion: 2014-10
• Study Completion: 2015-07
• Status Verified: 2017-09
• Last Update Submitted: 2017-09-19
• Last Update Posted: 2017-09-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 140

Inclusion Criteria

• Women between 18-50 years old with desire of children and needs of embryo transfer.
• Plasma prolactin less than 30.
• Uterine cavity that allow pregnancy, body mass index between 20-30.
• And signed consent inform.

Exclusion Criteria

• History of estrogen dependent cancer, unknown origin vaginal bleeding.
• Ovarian cyst.
• Contraindications to be pregnant.
• Estrogen allergy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Oral strogen	Oral strogen	-
Transdermal strogen	Transdermal strogen	-

Primary Outcome Measures

Name	Time	Method
Difference between day means in endometrial priming to achieve 7 mm.	11-16 days

Secondary Outcome Measures

Name	Time	Method
Biochemical Pregnancy rate	26-30 days	To calculate the biochemical pregnancy rate, we will divide the number of biochemical pregnancy into the number of embryonary transference and multiply by 100.
The patient's adherence to the recommended treatment.	1-16 days

Trial Locations

Locations (1)

Hospital del Mar; 🇪🇸 Barcelona, Spain